Enzon
Executive Summary
Signs non-exclusive licensing agreement with National Institutes of Health to develop cancer detection agents based on monoclonal antibodies developed by NIH. Enzon will continue the development of single-chain antigen-binding proteins (SCA) based on these MAbs, which include CC49, which may have potential in the detection of breast, lung and colorectal cancers. Enzon plans to file an IND for SCA-CC49 "later this year," the company says.